TY - JOUR
T1 - Safety and efficacy of a proteolytic enzyme for enzymatic burn débridement
T2 - A preliminary report
AU - Rosenberg, Lior
AU - Lapid, Oren
AU - Bogdanov-Berezovsky, Alex
AU - Glesinger, Ronen
AU - Krieger, Yuval
AU - Silberstein, Eldad
AU - Sagi, Amiram
AU - Judkins, Keith
AU - Singer, Adam J.
PY - 2004/12/1
Y1 - 2004/12/1
N2 - A prospective, non-comparative study design was used to describe our experience with a bromelain-derived debriding agent, Debridase, in 130 patients with 332 deep second degree and third degree burns treated between 1984 and 1999. Debridase was applied after saturating the burns with a moist dressing for 2-24 h. Debridase was applied for a period of 4 h under an occlusive dressing. Mean patient age was 18.6 ± 19.3, 42 (32.3%) were female, and 63 (48.5%) were children under age 18. Most burns were small. Debridase was applied once in 241 (72.6%) of the 332 wounds, twice in 67 (20.18%) cases, three times in 12 (3.61%) cases, and four times in 2 (0.6%) cases. The percentage débridement by number of applications was 89 ± 21% for a single application, 77 ± 27% for two, and 62 ± 27% for three Debridase applications, respectively. There were no significant adverse events. The availability of a fast acting, reliable and complication-free enzymatic debriding agent may open new horizons and provide a new treatment modality for burns.
AB - A prospective, non-comparative study design was used to describe our experience with a bromelain-derived debriding agent, Debridase, in 130 patients with 332 deep second degree and third degree burns treated between 1984 and 1999. Debridase was applied after saturating the burns with a moist dressing for 2-24 h. Debridase was applied for a period of 4 h under an occlusive dressing. Mean patient age was 18.6 ± 19.3, 42 (32.3%) were female, and 63 (48.5%) were children under age 18. Most burns were small. Debridase was applied once in 241 (72.6%) of the 332 wounds, twice in 67 (20.18%) cases, three times in 12 (3.61%) cases, and four times in 2 (0.6%) cases. The percentage débridement by number of applications was 89 ± 21% for a single application, 77 ± 27% for two, and 62 ± 27% for three Debridase applications, respectively. There were no significant adverse events. The availability of a fast acting, reliable and complication-free enzymatic debriding agent may open new horizons and provide a new treatment modality for burns.
KW - Burns
KW - Debridase
KW - Enzymatic débridement
UR - http://www.scopus.com/inward/record.url?scp=8844242612&partnerID=8YFLogxK
U2 - 10.1016/j.burns.2004.04.010
DO - 10.1016/j.burns.2004.04.010
M3 - Article
C2 - 15555800
AN - SCOPUS:8844242612
SN - 0305-4179
VL - 30
SP - 843
EP - 850
JO - Burns
JF - Burns
IS - 8
ER -